Exelixis, Inc. (EXEL)

43.83 -0.21 (-0.48%) USD  |  NASDAQ  |  Dec 31, 16:00
43.81 -0.02 (-0.05%) After-Hours: 20:00
More

Exelixis Revenue Estimates for Current Fiscal Year

Revenue Estimates for Current Fiscal Year Chart

View Revenue Estimates for Current Fiscal Year for EXEL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Current Fiscal Year Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Revenue Estimates for Current Fiscal Year Range, Past 5 Years

View Revenue Estimates for Current Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Current Fiscal Year Benchmarks

View Revenue Estimates for Current Fiscal Year Benchmarks
Start Trial
Vanda Pharmaceuticals, Inc. Upgrade
ADMA Biologics, Inc. Upgrade
Aldeyra Therapeutics, Inc. Upgrade
Neurocrine Biosciences, Inc. Upgrade
Axsome Therapeutics, Inc. Upgrade

Revenue Estimates for Current Fiscal Year Related Metrics

Revenue Estimates for Current Quarter Upgrade
Revenue Estimates for Next Quarter Upgrade
Revenue Estimates for Next Fiscal Year Upgrade
EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade